Verastem, Inc.
VSTM- 1D
- +16.1%
Verastem, Inc. in brief
Verastem, Inc. is a listed company in the Biotechnology industry, based in Needham, Massachusetts, USA. It was founded in 2010. Its market value was $1.1 B on 19 October 2026, which makes it the 8,924th largest listed company in the world and the 2,003rd largest in the USA on this site. In the year to December 2025 it had sales of $31 M and a net loss of $209 M. It employs about 48 people and Dan Paterson is its chief executive. Its shares trade under the symbol VSTM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Verastem, Inc.
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Verastem, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- 🔔· approximateInitial public offering on Nasdaq
- 2018
- •Legal Entity Identifier issuedLEI 549300IY0EFBIU8NQC81 registered.
- 2020
- 💰Record revenue of $89 millionFY2020, the highest of the 7 years on record.
Events of Verastem, Inc. from Wikidata, SEC EDGAR, the company record, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,686 (Jan 2020) · #2,795 (Jan 2021) · #3,314 (Jan 2022) · #4,530 (Dec 2022) · #3,383 (Jul 2023) · #3,197 (Jan 2024) · #1,323 (Mar 2026) · #2,428 (Aug 2026) · #2,095 (Oct 2026) · #2,004 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 35.3×
- Price / book
- 19.1×
- Free cash flow yield
- -9.6%
- Net margin
- -677.7%
- Operating margin
- -550.4%
- Return on equity
- -366.2%
- Liabilities / assets
- 76.8%
- Net debt
- $-48M
- Revenue growth
- +209.1%
- R&D / revenue
- 370.8%
- Revenue per employee
- $644 K
- Profit per employee
- $-4.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $31M | +209.1% | $-170M | $-209M | -677.7% |
| Dec 2024 | $10M | — | $-115M | $-131M | -1306.4% |
| Dec 2023 | — | — | $-92M | $-87M | — |
| Dec 2022 | $3M | +26.8% | $-73M | $-74M | -2838.8% |
| Dec 2021 | $2M | -97.7% | $-61M | $-71M | -3473.2% |
| Dec 2020 | $89M | +407.0% | $-49M | $-68M | -76.5% |
| Dec 2019 | $17M | -34.7% | $-132M | $-149M | -854.6% |
| Dec 2018 | $27M | — | $-95M | $-72M | -271.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-138M | — | — | $-3.02 | — |
| Dec 2024 | $-105M | $0M | $-105M | $-3.66 | — |
| Dec 2023 | $-86M | — | — | $-3.96 | — |
| Dec 2022 | $-64M | — | — | $-4.57 | — |
| Dec 2021 | $-54M | $0M | $-54M | $-4.90 | — |
| Dec 2020 | $-34M | $0M | $-34M | $-0.44 | — |
| Dec 2019 | $-139M | $0M | $-139M | $-2.00 | — |
| Dec 2018 | $-75M | $2M | $-76M | $-1.37 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $24M (+113.6% on a year earlier), net income $-75M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 20268-KCurrent reportRegulation FD disclosure
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Oct 14, 20268-KCurrent reportOther events
- Oct 14, 20268-KCurrent reportResults of operations · Directors or officers changed · Regulation FD disclosure · Other events
- Aug 7, 20268-KCurrent reportMaterial agreement · New financial obligation · Regulation FD disclosure
- Aug 6, 20268-KCurrent reportResults of operations
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jun 23, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 17, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 26, 20268-KCurrent reportShareholder vote
- May 7, 20268-KCurrent reportRegulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
Official filings of Verastem, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $31 M
- Operating income
- $-170 M
- Net income
- $-209 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $246 M
- Total liabilities
- $189 M
- Total equity
- $57 M
As of December-2025
Top 100 institutional investors in Verastem, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9,515,785 | +323,338 (+3.52%) | 7.55% | $77 M | Nov 13, 2026 |
| 2 | RTW Investments, LP | 6,718,081 | +82,288 (+1.24%) | 5.33% | $54 M | Nov 16, 2026 |
| 3 | Deep Track Capital, LP | 5,740,850 | 0 (0.00%) | 4.56% | $46 M | Nov 16, 2026 |
| 4 | Armistice Capital, LLC | 5,724,000 | -1,300,000 (-18.51%) | 4.54% | $46 M | Nov 16, 2026 |
| 5 | Rosalind Advisors, Inc. | 4,236,509 | +250,000 (+6.27%) | 3.36% | $34 M | Nov 16, 2026 |
| 6 | State Street Corp | 4,020,999 | -1,112,860 (-21.68%) | 3.19% | $32 M | Nov 12, 2026 |
| 7 | MPM Bioimpact LLC | 3,851,604 | New | 3.06% | $31 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 3,818,793 | -32,715 (-0.85%) | 3.03% | $31 M | Nov 13, 2026 |
| 9 | Foresite Capital Management VI LLC | 3,146,631 | 0 (0.00%) | 2.50% | $25 M | Nov 16, 2026 |
| 10 | Stonepine Capital Management, LLC | 3,042,775 | -306,852 (-9.16%) | 2.41% | $24 M | Nov 13, 2026 |
| 11 | Opaleye Management Inc. | 2,753,333 | +953,333 (+52.96%) | 2.18% | $22 M | Nov 16, 2026 |
| 12 | Vanguard Portfolio Management LLC | 2,555,924 | -710,946 (-21.76%) | 2.03% | $21 M | Nov 13, 2026 |
| 13 | Balyasny Asset Management L.P. | 2,299,020 | +612,445 (+36.31%) | 1.82% | $19 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 2,184,016 | +109,871 (+5.30%) | 1.73% | $18 M | Nov 6, 2026 |
| 15 | Morgan Stanley | 1,917,771 | +1,201,949 (+167.91%) | 1.52% | $15 M | Nov 13, 2026 |
| 16 | Nantahala Capital Management, LLC | 1,779,840 | -5,389,800 (-75.18%) | 1.41% | $14 M | Nov 13, 2026 |
| 17 | Acorn Capital Advisors, LLC | 1,469,153 | 0 (0.00%) | 1.17% | $12 M | Nov 16, 2026 |
| 18 | Goldman Sachs Group Inc | 1,443,118 | -1,278,060 (-46.97%) | 1.15% | $12 M | Nov 16, 2026 |
| 19 | Alyeska Investment Group, L.P. | 1,225,360 | -1,064,265 (-46.48%) | 0.97% | $10 M | Nov 16, 2026 |
| 20 | AIGH Capital Management LLC | 1,121,682 | -805,318 (-41.79%) | 0.89% | $9 M | Nov 2, 2026 |
| 21 | Franklin Templeton Inc | 1,105,850 | +829 (+0.08%) | 0.88% | $9 M | Nov 12, 2026 |
| 22 | NEXTBio Capital Management LP | 906,742 | -400,058 (-30.61%) | 0.72% | $7 M | Nov 13, 2026 |
| 23 | Point72 Asset Management, L.P. | 901,995 | New | 0.72% | $7 M | Nov 16, 2026 |
| 24 | Bank Of America Corp /de/ | 849,889 | -40,086 (-4.50%) | 0.67% | $7 M | Nov 16, 2026 |
| 25 | FMR LLC | 842,128 | +215,830 (+34.46%) | 0.67% | $7 M | Nov 10, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | AQR Capital Management LLC | 798,754 | -135,811 (-14.53%) | 0.63% | $6 M | Nov 16, 2026 |
| 27 | Panagora Asset Management Inc | 715,865 | +48,991 (+7.35%) | 0.57% | $6 M | Nov 12, 2026 |
| 28 | Hennion & Walsh Asset Management, Inc. | 699,828 | +130,633 (+22.95%) | 0.56% | $6 M | Oct 13, 2026 |
| 29 | Pinnacle Financial Partners, Inc. | 695,880 | -390,560 (-35.95%) | 0.55% | $6 M | Nov 13, 2026 |
| 30 | Northern Trust Corp | 671,489 | +19,994 (+3.07%) | 0.53% | $5 M | Nov 16, 2026 |
| 31 | Barclays PLC | 671,045 | +577,637 (+618.40%) | 0.53% | $5 M | Nov 6, 2026 |
| 32 | Citigroup Inc | 628,458 | +508,223 (+422.69%) | 0.50% | $5 M | Nov 4, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 609,042 | -7,820 (-1.27%) | 0.48% | $5 M | Nov 13, 2026 |
| 34 | Jane Street Group, LLC | 467,585 | New | 0.37% | $4 M | Nov 12, 2026 |
| 35 | Torray Investment Partners LLC | 464,381 | -13,074 (-2.74%) | 0.37% | $4 M | Oct 30, 2026 |
| 36 | Trexquant Investment LP | 454,265 | New | 0.36% | $4 M | Nov 16, 2026 |
| 37 | Exome Asset Management LLC | 429,041 | 0 (0.00%) | 0.34% | $3 M | Nov 16, 2026 |
| 38 | UBS Group AG | 427,736 | -176,744 (-29.24%) | 0.34% | $3 M | Nov 10, 2026 |
| 39 | Jefferies Financial Group Inc. | 414,241 | -82,288 (-16.57%) | 0.33% | $3 M | Nov 5, 2026 |
| 40 | Virtus Investment Advisers, LLC | 411,097 | +127,467 (+44.94%) | 0.33% | $3 M | Nov 12, 2026 |
| 41 | Ameriprise Financial Inc | 384,936 | New | 0.31% | $3 M | Nov 16, 2026 |
| 42 | Raymond James Financial Inc | 339,834 | +140,997 (+70.91%) | 0.27% | $3 M | Nov 12, 2026 |
| 43 | Palo Alto Investors LP | 325,480 | +15,795 (+5.10%) | 0.26% | $3 M | Nov 16, 2026 |
| 44 | Woodline Partners LP | 313,911 | New | 0.25% | $3 M | Nov 16, 2026 |
| 45 | Susquehanna International Group, LLP | 311,851 | +73,422 (+30.79%) | 0.25% | $3 M | Nov 16, 2026 |
| 46 | Millennium Management LLC | 295,622 | -1,782,381 (-85.77%) | 0.23% | $2 M | Nov 16, 2026 |
| 47 | Wellington Management Group LLP | 268,490 | +216,790 (+419.32%) | 0.21% | $2 M | Nov 16, 2026 |
| 48 | Nuveen, LLC | 260,452 | +1,519 (+0.59%) | 0.21% | $2 M | Nov 10, 2026 |
| 49 | Charles Schwab Investment Management Inc | 251,846 | +7,896 (+3.24%) | 0.20% | $2 M | Nov 16, 2026 |
| 50 | Ikarian Capital, LLC | 213,865 | 0 (0.00%) | 0.17% | $2 M | Nov 16, 2026 |
| 51 | Bank of New York Mellon Corp | 203,807 | +18,863 (+10.20%) | 0.16% | $2 M | Nov 5, 2026 |
| 52 | BNP Paribas Financial Markets | 193,418 | +181,985 (+1591.75%) | 0.15% | $2 M | Nov 12, 2026 |
| 53 | Toronto Dominion Bank | 184,229 | -276,184 (-59.99%) | 0.15% | $1 M | Nov 16, 2026 |
| 54 | Jump Financial, LLC | 176,874 | -130,626 (-42.48%) | 0.14% | $1 M | Nov 13, 2026 |
| 55 | Janney Montgomery Scott LLC | 152,647 | +208 (+0.14%) | 0.12% | $1 M | Nov 12, 2026 |
| 56 | Weiss Asset Management LP | 143,819 | New | 0.11% | $1 M | Nov 16, 2026 |
| 57 | Quantinno Capital Management LP | 137,023 | +90,686 (+195.71%) | 0.11% | $1 M | Nov 13, 2026 |
| 58 | Creative Planning | 120,745 | +73,157 (+153.73%) | 0.10% | $1 M | Nov 2, 2026 |
| 59 | Invesco Ltd. | 120,272 | -4,805 (-3.84%) | 0.10% | $1 M | Nov 12, 2026 |
| 60 | Royal Bank Of Canada | 103,174 | -5,689 (-5.23%) | 0.08% | $1 M | Nov 16, 2026 |
| 61 | Rafferty Asset Management, LLC | 97,537 | +3,333 (+3.54%) | 0.08% | $1 M | Nov 13, 2026 |
| 62 | Rhumbline Advisers | 90,349 | +6,671 (+7.97%) | 0.07% | $1 M | Nov 10, 2026 |
| 63 | Alliancebernstein L.P. | 83,050 | -34,040 (-29.07%) | 0.07% | $1 M | Nov 16, 2026 |
| 64 | Deutsche Bank AG\ | 77,867 | -9,801 (-11.18%) | 0.06% | $1 M | Nov 6, 2026 |
| 65 | ADAR1 Capital Management, LLC | 72,800 | -3,000 (-3.96%) | 0.06% | $1 M | Nov 16, 2026 |
| 66 | Entropy Technologies, LP | 70,240 | New | 0.06% | $1 M | Nov 13, 2026 |
| 67 | Boothbay Fund Management, LLC | 68,541 | 0 (0.00%) | 0.05% | $1 M | Nov 16, 2026 |
| 68 | Price T Rowe Associates Inc /MD/ | 65,565 | 0 (0.00%) | 0.05% | $1 M | Nov 16, 2026 |
| 69 | Engineers Gate Manager LP | 60,053 | New | 0.05% | $0 M | Nov 16, 2026 |
| 70 | Mercer Global Advisors Inc /adv | 59,732 | +16,929 (+39.55%) | 0.05% | $0 M | Nov 16, 2026 |
| 71 | SEI Investments Co | 58,034 | +31,412 (+117.99%) | 0.05% | $0 M | Nov 10, 2026 |
| 72 | Russell Investments Group, Ltd. | 56,851 | +27,273 (+92.21%) | 0.05% | $0 M | Nov 6, 2026 |
| 73 | Aquatic Capital Management LLC | 56,481 | New | 0.04% | $0 M | Nov 16, 2026 |
| 74 | Public Employees Retirement System Of Ohio | 51,218 | New | 0.04% | $0 M | Nov 16, 2026 |
| 75 | Jpmorgan Chase & Co | 49,888 | +14,501 (+40.98%) | 0.04% | $0 M | Nov 12, 2026 |
| 76 | MetLife Investment Management, LLC | 47,399 | -11,850 (-20.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 46,692 | -876 (-1.84%) | 0.04% | $0 M | Nov 16, 2026 |
| 78 | WINTON GROUP Ltd | 46,600 | +22,400 (+92.56%) | 0.04% | $0 M | Nov 12, 2026 |
| 79 | Cetera Investment Advisers | 42,885 | -527 (-1.21%) | 0.03% | $0 M | Nov 13, 2026 |
| 80 | Envestnet Asset Management Inc | 42,837 | -1,744 (-3.91%) | 0.03% | $0 M | Nov 16, 2026 |
| 81 | Stifel Financial Corp | 38,047 | -306 (-0.80%) | 0.03% | $0 M | Nov 12, 2026 |
| 82 | Renaissance Technologies LLC | 34,940 | New | 0.03% | $0 M | Nov 12, 2026 |
| 83 | Profund Advisors LLC | 34,687 | -12,797 (-26.95%) | 0.03% | $0 M | Oct 29, 2026 |
| 84 | Wells Fargo & Company/mn | 34,052 | -46,635 (-57.80%) | 0.03% | $0 M | Nov 16, 2026 |
| 85 | Aries Wealth Management | 32,833 | +2,000 (+6.49%) | 0.03% | $0 M | Oct 23, 2026 |
| 86 | Diversified Trust Co | 32,245 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 87 | Nomura Holdings Inc | 31,488 | New | 0.03% | $0 M | Nov 16, 2026 |
| 88 | XTX Topco Ltd | 31,057 | -530,734 (-94.47%) | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Vanguard Global Advisers, LLC | 30,905 | +385 (+1.26%) | 0.02% | $0 M | Nov 13, 2026 |
| 90 | Gotham Asset Management, LLC | 30,600 | New | 0.02% | $0 M | Nov 16, 2026 |
| 91 | Quadrature Capital Ltd | 30,599 | -16,383 (-34.87%) | 0.02% | $0 M | Nov 13, 2026 |
| 92 | iA Global Asset Management Inc. | 30,108 | New | 0.02% | $0 M | Oct 29, 2026 |
| 93 | Squarepoint Ops LLC | 29,739 | New | 0.02% | $0 M | Nov 9, 2026 |
| 94 | New York State Common Retirement Fund | 27,700 | +22,500 (+432.69%) | 0.02% | $0 M | Nov 17, 2026 |
| 95 | Fox Run Management, L.L.C. | 25,641 | New | 0.02% | $0 M | Nov 12, 2026 |
| 96 | Police & Firemen's Retirement System of New Jersey | 23,122 | +3,737 (+19.28%) | 0.02% | $0 M | Nov 9, 2026 |
| 97 | Tower Research Capital LLC (TRC) | 22,664 | +15,105 (+199.83%) | 0.02% | $0 M | Nov 16, 2026 |
| 98 | Manufacturers Life Insurance Company, The | 21,932 | -322 (-1.45%) | 0.02% | $0 M | Nov 13, 2026 |
| 99 | Vanguard Personalized Indexing Management, LLC | 21,903 | +9,949 (+83.23%) | 0.02% | $0 M | Nov 16, 2026 |
| 100 | Wealth Enhancement Advisory Services, LLC | 19,745 | +246 (+1.26%) | 0.02% | $0 M | Oct 13, 2026 |
Mutual funds holding Verastem, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 3.39 M | $13 M | 2.7% | 0.12% | +68% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.81 M | $11 M | 2.2% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 1.40 M | $8 M | 1.1% | 0.04% | +357% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.07 M | $8 M | 1.6% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 872,784 | $5 M | 0.69% | 0.01% | +32% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 960,598 | $4 M | 0.76% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 701,337 | $3 M | 0.56% | 0.06% | +239% | May 29, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 750,135 | $3 M | 0.60% | 0.02% | +146% | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 401,744 | $2 M | 0.32% | 0.20% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 575,899 | $2 M | 0.46% | 0.04% | +37% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 536,651 | $2 M | 0.43% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 378,589 | $2 M | 0.30% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC | 260,400 | $2 M | 0.21% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 343,561 | $1 M | 0.27% | <0.01% | +30% | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 330,409 | $1 M | 0.26% | 0.07% | +382% | Jun 30, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 295,455 | $1 M | 0.23% | 0.19% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 194,439 | $1 M | 0.15% | 0.01% | +32% | Jul 31, 2026 |
| 🇺🇸 iShares Genomics Immunology and Healthcare ETFBlackRock Fund Advisors | 178,719 | $1 M | 0.14% | 0.54% | +54% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 268,301 | $1 M | 0.21% | 0.07% | +59% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 125,896 | $1 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 115,157 | $1 M | 0.09% | 0.14% | −2.0% | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 173,404 | $1 M | 0.14% | <0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 170,345 | $1 M | 0.14% | 0.08% | +99% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 106,415 | $1 M | 0.08% | 0.02% | +33% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 133,691 | $1 M | 0.11% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 149,314 | $1 M | 0.12% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 128,379 | $1 M | 0.10% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 83,454 | $0 M | 0.07% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 109,968 | $0 M | 0.09% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 81,901 | $0 M | 0.06% | 0.02% | +5.3% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 78,050 | $0 M | 0.06% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 58,252 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 86,908 | $0 M | 0.07% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 75,130 | $0 M | 0.06% | 0.02% | +50% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 74,795 | $0 M | 0.06% | 0.02% | +162% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 49,159 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 64,022 | $0 M | 0.05% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 45,927 | $0 M | 0.04% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 53,429 | $0 M | 0.04% | <0.01% | +49% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 58,800 | $0 M | 0.05% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 37,988 | $0 M | 0.03% | 0.01% | +31% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 55,509 | $0 M | 0.04% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 36,349 | $0 M | 0.03% | 0.11% | — | Apr 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 30,578 | $0 M | 0.02% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 42,609 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 41,960 | $0 M | 0.03% | <0.01% | +146% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 41,768 | $0 M | 0.03% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 41,412 | $0 M | 0.03% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 35,015 | $0 M | 0.03% | <0.01% | +27% | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 38,739 | $0 M | 0.03% | <0.01% | +97% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 37,586 | $0 M | 0.03% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 34,308 | $0 M | 0.03% | 0.01% | +94% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 29,304 | $0 M | 0.02% | 0.01% | −35% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 27,713 | $0 M | 0.02% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 30,754 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 20,152 | $0 M | 0.02% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 29,828 | $0 M | 0.02% | 0.08% | +270% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 18,933 | $0 M | 0.02% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 25,900 | $0 M | 0.02% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 22,643 | $0 M | 0.02% | <0.01% | +32% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 22,930 | $0 M | 0.02% | <0.01% | +38% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 12,762 | $0 M | 0.01% | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 12,757 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 17,836 | $0 M | 0.01% | 0.03% | +49% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 17,727 | $0 M | 0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 17,450 | $0 M | 0.01% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 16,774 | $0 M | 0.01% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 15,983 | $0 M | 0.01% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 10,704 | $0 M | <0.01% | 0.03% | — | Mar 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 9,462 | $0 M | <0.01% | <0.01% | +9.8% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 14,323 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,354 | $0 M | <0.01% | 0.02% | +51% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 11,200 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 12,696 | $0 M | 0.01% | 0.03% | +310% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 12,530 | $0 M | <0.01% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 12,084 | $0 M | <0.01% | <0.01% | +123% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 12,044 | $0 M | <0.01% | <0.01% | +77% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 11,690 | $0 M | <0.01% | 0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 11,598 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,538 | $0 M | <0.01% | 0.02% | +35% | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 6,891 | $0 M | <0.01% | <0.01% | +172% | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 10,378 | $0 M | <0.01% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,234 | $0 M | <0.01% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 5,730 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 5,492 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 7,275 | $0 M | <0.01% | 0.02% | +164% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 7,056 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 5,907 | $0 M | <0.01% | <0.01% | +64% | May 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 4,267 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,378 | $0 M | <0.01% | <0.01% | +70% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 5,705 | $0 M | <0.01% | 0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 5,483 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 5,239 | $0 M | <0.01% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,000 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 2,833 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION | 3,750 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,997 | $0 M | <0.01% | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 3,154 | $0 M | <0.01% | <0.01% | +36% | May 31, 2026 |
| 🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust | 3,560 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,192 | $0 M | <0.01% | <0.01% | +68% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Verastem, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Dan PatersonPresident and CEO, Director | Sell10b5-1 plan | -1,299 | $9.600 | $12 K | 651,413 | Form 4 |
| filed | Dan PatersonPresident and CEO, Director | Sell10b5-1 plan | -44,121 | $8.000 | $353 K | 652,712 | Form 4 |
| filed | Daniel CalkinsChief Financial Officer | Sell10b5-1 plan | -2,566 | $8.000 | $21 K | 123,781 | Form 4 |
| filed | Dan PatersonPresident and CEO, Director | Grant or award10b5-1 plan | -106,893 | — | — | 696,833 | Form 4 |
| filed | Daniel CalkinsChief Financial Officer | Grant or award10b5-1 plan | -8,333 | — | — | 126,347 | Form 4 |
| filed | Daniel CalkinsChief Financial Officer | Sell10b5-1 plan | -55 | $7.700 | $424 | 118,014 | Form 4 |
| filed | Dan PatersonPresident and CEO, Director | Sell10b5-1 plan | -1,302 | $5.810 | $8 K | 589,940 | Form 4 |
| filed | Daniel CalkinsChief Financial Officer | Sell10b5-1 plan | -4,032 | $4.180 | $17 K | 117,295 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Verastem, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-14 13:42 UTC, code LUDP, resumed 13:47 UTC
- 2025-05-08 15:10 UTC, code T3, resumed 17:45 UTC
Fails to deliver
- : 20,741 shares at $8.65
- : 31,567 shares at $7.71
- : 107,998 shares at $7.45
- : 148,209 shares at $8.11
- : 216,889 shares at $8.27
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Verastem, Inc. scorecard#
Passes 3 of the 17 checks that could be worked out: strongest in growth (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 19, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median19.1×Price to book 19.1× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median35.3×Price to sales 35.3× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-9.6%Free cash flow is -9.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- ✓Revenue grew in the newest year209.1%Revenue up 209.1% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.02 vs -3.66Diluted EPS -3.02 in fiscal 2025 against -3.66 the year before (report's currency).
- ✗Net income higher than five years earlier-$209 M-$209 M in fiscal 2025 against -$68 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$209 MNet income -$209 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-550.4%-550.4% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-550.4%-550.4% in fiscal 2025 against -2805.4% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities3.1×Current ratio 3.09 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-149.2×Operating income -149.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-4.58Z-score -4.58 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year94.1%Diluted shares up 94.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Verastem, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -550.4% | -60.5% | |
| Net margin | -677.7% | -68.9% | |
| Revenue growth | 209.1% | 15.8% |
4of 7on the Piotroski tests of financial strength
- Net loss of $209 million, the 15th loss-making year in a row.
- The share count rose 94.1% in the year.
- Operating income covers the interest bill only -149.2 times.
Verastem, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 31+209%100% | 10—100% | — | 2.6+26.4%100% | 2.1−97.7%100% | 89+407%100% | 17−34.7%100% | 27—100% | — | — | |
| Cost of revenue | — | — | — | — | — | — | — | 0.2—0.6% | — | — | |
| Research and development | 115+40.9%371% | 81+32.6%813% | 61+21.4%— | 51+28.5%1948% | 39−4.9%1917% | 41−9.6%46.7% | 46+4.9%262% | 44−6.0%163% | 46+135%— | 20—— | |
| Selling, general and administrative | 81+86.0%262% | 44+42.0%436% | 31+23.0%— | 25+3.6%962% | 24−61.6%1175% | 63−38.0%70.9% | 101+31.0%580% | 77+261%289% | 21+24.1%— | 17—— | |
| General and administrative | — | — | — | — | — | — | — | — | 21+24.1%— | 17—— | |
| Operating expenses | — | — | — | — | — | — | — | 122+79.2%455% | 68+83.2%— | 37—— | |
| Total costs and expenses | 201+60.9%650% | 125+35.7%1250% | 92+21.9%— | 76+19.0%2910% | 63−54.0%3091% | 138−8.0%156% | 150+23.3%858% | 122+79.2%455% | 68—— | — | |
| Operating income | −170—−550% | −115—−1150% | −92—— | −73—−2810% | −61—−2991% | −49—−55.8% | −132—−758% | −95—−355% | −68—— | −37—— | |
| Interest and finance income | 4.1−2.0%13.2% | 4.1−33.2%41.5% | 6.2+411%— | 1.2+571%46.8% | 0.2−64.9%8.8% | 0.5−88.2%0.6% | 4.4+68.3%25.1% | 2.6+364%9.7% | 0.6−0.2%— | 0.6—— | |
| Interest expense and finance costs | 1.1−75.1%3.7% | 4.6+10.2%45.6% | 4.1+93.7%— | 2.1−78.6%82.3% | 10.0−36.9%486% | 16−23.4%17.8% | 21+255%118% | 5.8+939%21.7% | 0.6—— | — | |
| Other non-operating income (expense) | −0.2—−0.7% | −0.1—−1.2% | −0.1−332%— | 0.0—1.8% | — | −1.3—−1.5% | −0.6−103%−3.7% | 26—95.7% | — | — | |
| Income before tax | −209—−678% | −130—−1305% | −87—— | −74—−2843% | −71—−3468% | −68—−76.3% | −149—−855% | −72—−271% | — | — | |
| Income tax | — | 0.2—1.8% | — | 0—0.0% | 0−100%0.0% | 0.2—0.2% | 0—0.0% | 0—0.0% | — | — | |
| Net income including minority interests | −209—−678% | −131—−1306% | −87—— | −74—−2843% | −71—−3468% | −68—−76.5% | −149—−855% | −72—−271% | −68—— | −36—— | |
| Net income attributable to shareholders | −209—−678% | −131—−1306% | −87—— | −74—−2843% | −71—−3468% | −68—−76.5% | −149—−855% | −72—−271% | −68—— | −36—— | |
| Earnings per share, basic | -3.02—— | -3.66—— | -3.96—— | -4.57r-0.38—— | -4.90r-0.41—— | -0.44—— | -2.00—— | -1.12—— | -1.76—— | -0.99—— | |
| Earnings per share, diluted | -3.02—— | -3.66—— | -3.96r-3.93—— | -4.57r-0.38—— | -4.90r-0.41—— | -0.44—— | -2.00—— | -1.37—— | -1.76—— | -0.99—— | |
| Shares, weighted average (basic) | 69+94.1%— | 36+61.9%— | 22+36.7%— | 16r194+11.0%— | 15r174−90.5%— | 153+106%— | 75+14.8%— | 65+69.1%— | 38+3.9%— | 37—— | |
| Shares, weighted average (diluted) | 69+94.1%— | 36+61.9%— | 22+36.7%— | 16r0.2+11.0%— | 15r174+9380%— | 0.2r153−99.8%— | 75+7.6%— | 69+80.4%— | 38+3.9%— | 37—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 205+131%83.2% | 89+14.0%87.5% | 78+4.0%52.0% | 75+253%78.8% | 21−68.6%19.6% | 68+55.8%43.9% | 44−66.5%30.0% | 130+58.0%46.8% | 82+154%91.5% | 32—38.7% | |
| Short-term investments | — | — | 59+357%39.6% | 13−83.6%13.6% | 79+7.6%72.7% | 73+130%47.6% | 32−73.3%22.1% | 120+2564%43.2% | 4.5—5.0% | — | |
| Inventory | 1.8—0.7% | — | — | — | — | — | 3.1+847%2.1% | 0.3—0.1% | — | — | |
| Other current assets | 7.6+27.5%3.1% | 5.9−9.3%5.9% | 6.6+32.5%4.4% | 4.9−0.5%5.2% | 5.0+43.0%4.6% | 3.5−9.4%2.3% | 3.8r3.8+29.0%2.6% | 3.0+167%1.1% | 1.1+180%1.2% | 0.4—0.5% | |
| Current assets | 223+135%90.7% | 95−33.9%93.5% | 144+54.7%96.0% | 93−12.2%97.7% | 106−27.0%97.3% | 145+70.6%93.9% | 85−66.5%58.6% | 253+188%91.4% | 88+8.0%97.8% | 81—97.2% | |
| Property, plant and equipment | — | 0.0−13.5%0.0% | 0.0−59.8%0.0% | 0.1−56.2%0.1% | 0.2−49.5%0.2% | 0.4−56.1%0.3% | 0.9−30.8%0.7% | 1.4+59.0%0.5% | 0.9−39.2%1.0% | 1.4—1.7% | |
| Right-of-use (leased) assets | 0.5−65.1%0.2% | 1.4+20.0%1.4% | 1.2−34.5%0.8% | 1.8−22.3%1.9% | 2.3−15.6%2.1% | 2.7−11.4%1.8% | 3.1—2.1% | — | — | — | |
| Other intangible assets | 16—6.7% | — | — | — | — | — | 20−7.3%13.8% | 22—7.8% | — | — | |
| Long-term investments | — | — | — | — | — | 6.0—3.9% | — | — | — | — | |
| Total assets | 246+143%100% | 102−32.2%100% | 150+57.5%100% | 95−12.5%100% | 109−29.6%100% | 154+6.4%100% | 145−47.7%100% | 277+209%100% | 90+7.4%100% | 84—100% | |
| Accounts payable | 12+209%5.1% | 4.0−44.0%4.0% | 7.2+46.6%4.8% | 4.9+113%5.2% | 2.3+22.8%2.1% | 1.9−80.6%1.2% | 9.7−5.8%6.7% | 10+11.6%3.7% | 9.2+124%10.2% | 4.1—4.9% | |
| Current liabilities | 72+133%29.3% | 31+17.4%30.5% | 26+21.8%17.6% | 22+16.5%22.8% | 19+8.8%17.1% | 17−42.8%11.1% | 30−19.4%20.6% | 37+116%13.4% | 17+55.8%19.1% | 11—13.1% | |
| Long-term debt | — | — | — | — | — | — | — | — | 15—16.5% | — | |
| Lease liabilities (non-current) | — | 0.5+0.9%0.5% | 0.5−63.9%0.4% | 1.5−35.1%1.5% | 2.3−22.8%2.1% | 2.9−16.0%1.9% | 3.5—2.4% | — | — | — | |
| Total liabilities | 189+45.1%76.8% | 130+83.2%128% | 71+49.4%47.5% | 48+126%50.1% | 21−46.0%19.4% | 39−71.7%25.3% | 138−9.9%95.1% | 153+376%55.2% | 32+183%35.8% | 11—13.6% | |
| Retained earnings | −1,165—−473% | −956—−941% | −825—−551% | −738—−776% | −664—−611% | −593—−384% | −525—−362% | −376—−135% | −303—−338% | −235—−281% | |
| Shareholders' equity | 57—23.2% | −29−150%−28.5% | 57+21.1%38.3% | 47−45.9%49.9% | 88−24.0%80.6% | 115+1507%74.7% | 7.2−94.2%4.9% | 124+115%44.8% | 58−20.2%64.2% | 72—86.4% | |
| Total liabilities and equity | 246+143%100% | 102−32.2%100% | 150+57.5%100% | 95−12.5%100% | 109−29.6%100% | 154+6.4%100% | 145−47.7%100% | 277+209%100% | 90+7.4%100% | 84—100% | |
| Shares outstanding | 78+73.6%— | 45+77.1%— | 25+51.3%— | 17r201−91.0%— | 185+8.7%— | 170+113%— | 80+8.6%— | 74+45.3%— | 51+37.3%— | 37—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0.7—— | |
| Share-based compensation | 9.4+28.1%30.4% | 7.3+25.3%73.4% | 5.9−3.1%— | 6.0−21.6%233% | 7.7−5.0%376% | 8.1−4.9%9.2% | 8.5+28.0%48.9% | 6.7+32.5%25.0% | 5.0−19.9%— | 6.3—— | |
| Cash from operating activities | −138—−445% | −105—−1048% | −86—— | −64—−2453% | −54—−2606% | −34—−37.9% | −139—−794% | −75—−279% | −57—— | −29—— | |
| Capital expenditure | — | −0.0—−0.3% | — | — | −0.2—−9.5% | −0.0—−0.0% | −0.0—−0.0% | −1.5—−5.6% | — | −0.0—— | |
| Intangible assets bought | −9.6—−31.1% | — | — | — | — | — | — | −22—−82.3% | — | — | |
| Cash from investing activities | −9.6−116%−31.1% | 60—600% | −44−167%— | 66+75975%2549% | 0.1—4.2% | −47−153%−53.5% | 90—513% | −138−415%−518% | 44+19.0%— | 37r37—— | |
| Debt issued | — | — | — | — | — | — | — | — | 15—— | — | |
| Debt repaid | −43—−138% | — | −0.3—— | — | — | −37—−42.2% | −12—−69.7% | — | — | — | |
| Shares issued | 197+1285%637% | 14−84.4%142% | 91+234%— | 27+307%1054% | 6.7−93.7%327% | 106—120% | — | 105+119%394% | 48—— | — | |
| Cash from financing activities | 263+381%852% | 55−59.2%548% | 134+159%— | 52+652%1995% | 6.9−90.1%335% | 70—78.7% | −2.4−101%−14.0% | 261+313%977% | 63—— | −0.0—— | |
| Change in cash | 116+1064%376% | 10.0+204%99.8% | 3.3−93.9%— | 54—2092% | −47—−2266% | −11—−12.7% | −51−206%−294% | 48−3.1%181% | 50+570%— | 7.4r7.5—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 100—100% | 24+114%100% | 40+1775%100% | 19—100% | 18*—100% | 11—100% | 2.1−78.6%100% | — | 0*—— | 0*—— | 10—100% | — | — | |
| Research and development | 180+73.5%180% | 69+137%287% | 41+66.8%103% | 38+31.1%205% | 32*+52.2%181% | 29+17.1%258% | 25+37.2%1160% | 29+64.6%— | 21*−7.5%— | 25—— | 18—181% | 18—— | 23*—— | |
| Selling, general and administrative | 101+49.1%100% | 26+26.1%110% | 27+32.6%68.4% | 22+48.4%119% | 24*+127%139% | 21+71.1%187% | 21+102%967% | 15+45.1%— | 11*+24.8%— | 12—— | 10—102% | 10—— | 8.6*—— | |
| General and administrative | — | 7.4+9.4%30.8% | 8.5+14.2%21.3% | — | — | 6.8—60.2% | 7.5—350% | — | — | — | — | — | — | |
| Total costs and expenses | 295+69.7%294% | 99+91.0%413% | 73+58.6%182% | 64+43.9%340% | 59*+86.8%337% | 52+40.3%462% | 46+62.3%2148% | 44+57.4%— | 32*+1.4%— | 37—— | 28—283% | 28—— | 31*—— | |
| Operating income | −194—−194% | −75—−313% | −33—−81.6% | −45—−240% | −41*—−237% | −41—−362% | −44—−2048% | −44—— | −32*—— | −37—— | −18—−183% | −28—— | −31*—— | |
| Interest and finance income | 4.3+8.7%4.3% | 0.8−35.3%3.2% | 1.1+34.8%2.8% | 1.3+35.1%6.9% | 1.1*+14.0%6.3% | 1.2+42.2%10.5% | 0.8−16.4%38.5% | 1.0−29.8%— | 1.0*−48.2%— | 0.8—— | 1.0—9.8% | 1.4—— | 1.9*—— | |
| Interest expense and finance costs | 1.4−26.8%1.4% | 0.2−33.5%0.9% | 0.4+69.8%0.9% | 0.4+99.0%2.0% | 0.4*−63.8%2.4% | 0.3−72.2%2.8% | 0.2−81.4%9.9% | 0.2−83.0%— | 1.1*+2.3%— | 1.1—— | 1.1—11.4% | 1.1—— | 1.1*—— | |
| Other non-operating income (expense) | −0.2—−0.2% | −0.1—−0.2% | −0.1—−0.1% | −0.1—−0.3% | −0.0*−313%−0.1% | −0.0—−0.3% | −0.1—−5.1% | −0.0—— | 0.0*—— | −0.1—— | −0.0—−0.2% | −0.0—— | −0.0*—— | |
| Income before tax | — | −75—−311% | −34—−84.5% | — | −33*—−188% | −99—−876% | −26—−1214% | — | — | — | — | — | — | |
| Income tax | — | 0—0.0% | 0.8—2.0% | 0—0.0% | — | 0*—0.0% | 0*—0.0% | 0—— | 0.2*—— | 0—— | 0—0.0% | 0—— | — | |
| Net income including minority interests | −179—−178% | −75*—−311% | −35*—−86.5% | −37—−196% | −33*—−188% | −99*—−876% | −26*—−1214% | −52—— | −65*—— | −24*—— | −8.3*—−82.6% | −34—— | −27*—— | |
| Net income attributable to shareholders | −179—−178% | −75—−311% | −35—−86.5% | −37—−196% | −33*—−188% | −99—−876% | −26—−1214% | −52—— | −65*—— | −24—— | −8.3—−82.6% | −34—— | −27*—— | |
| Earnings per share, basic | — | -0.74—— | -0.35—— | -0.37—— | — | -1.35—— | -0.39—— | -0.96—— | — | -0.60—— | -0.31—— | -1.26—— | — | |
| Earnings per share, diluted | — | -0.74—— | -0.35—— | -0.46—— | — | -1.35—— | -0.62—— | -0.96—— | — | -0.60—— | -0.31—— | -1.26—— | — | |
| Shares, weighted average (basic) | 101+38.4%— | 101+38.4%— | 100+51.4%— | 98+81.4%— | — | 73+81.7%— | 66+146%— | 54+102%— | — | 40—— | 27—— | 27—— | — | |
| Shares, weighted average (diluted) | 101+38.4%— | 101+38.4%— | 100+35.2%— | 99+83.0%— | — | 73+81.7%— | 74+176%— | 54+102%— | — | 40—— | 27—— | 27—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 173—75.2% | 173+25.5%75.2% | 136−17.0%66.0% | 166+40.8%72.7% | 205+131%83.2% | 138+21.7%77.9% | 164+97.1%83.7% | 118+44.6%89.3% | 89+14.0%87.5% | 113—89.6% | 83—78.8% | 81—65.8% | 78—52.0% | |
| Short-term investments | — | — | — | 16—7.1% | — | — | — | — | — | — | — | 29—23.3% | 59—39.6% | |
| Inventory | 2.3—1.0% | 2.3+25.5%1.0% | 2.4+105%1.2% | 2.3—1.0% | 1.8—0.7% | 1.8—1.0% | 1.2—0.6% | — | — | — | — | — | — | |
| Other current assets | 14—6.2% | 14+86.5%6.2% | 8.3+28.0%4.0% | 8.6+23.8%3.8% | 7.6+27.5%3.1% | 7.6+4.8%4.3% | 6.5+19.4%3.3% | 6.9−5.4%5.3% | 5.9−9.3%5.9% | 7.3—5.8% | 5.5—5.2% | 7.3—5.9% | 6.6—4.4% | |
| Current assets | 199—86.8% | 199+29.4%86.8% | 176+1.1%85.3% | 203+62.7%89.1% | 223+135%90.7% | 154+27.7%87.1% | 174+74.9%88.8% | 125+6.0%94.7% | 95−33.9%93.5% | 121—95.5% | 100—94.2% | 118—95.3% | 144—96.0% | |
| Property, plant and equipment | — | — | — | — | — | 0.0−48.7%0.0% | 0.0−54.3%0.0% | 0.0−57.7%0.0% | 0.0−13.5%0.0% | 0.0—0.0% | 0.0—0.0% | 0.1—0.0% | 0.0—0.0% | |
| Right-of-use (leased) assets | 2.5—1.1% | 2.5+236%1.1% | 2.6+173%1.3% | 2.8+135%1.2% | 0.5−65.1%0.2% | 0.7+16.8%0.4% | 1.0+18.0%0.5% | 1.2+19.2%0.9% | 1.4+20.0%1.4% | 0.6—0.5% | 0.8—0.8% | 1.0—0.8% | 1.2—0.8% | |
| Other intangible assets | 16—6.8% | 16−6.7%6.8% | 16+1.5%7.7% | 16—7.1% | 16—6.7% | 17—9.4% | 16—8.0% | — | — | — | — | — | — | |
| Total assets | 230—100% | 230+29.8%100% | 207+5.2%100% | 228+73.0%100% | 246+143%100% | 177+39.9%100% | 196+85.6%100% | 132+6.6%100% | 102−32.2%100% | 126—100% | 106—100% | 124—100% | 150—100% | |
| Accounts payable | 20—8.8% | 20+105%8.8% | 18+124%8.7% | 9.6+33.4%4.2% | 12+209%5.1% | 9.9+123%5.6% | 8.0+20.5%4.1% | 7.2−3.4%5.5% | 4.0−44.0%4.0% | 4.4—3.5% | 6.7—6.3% | 7.4—6.0% | 7.2—4.8% | |
| Current liabilities | 103—45.0% | 103+73.0%45.0% | 78+55.1%37.8% | 67+87.7%29.3% | 72+133%29.3% | 60+59.8%33.8% | 50+66.0%25.7% | 36+33.3%27.0% | 31+17.4%30.5% | 37—29.6% | 30—28.7% | 27—21.6% | 26—17.6% | |
| Lease liabilities (non-current) | 1.9—0.8% | 1.9—0.8% | 2.1—1.0% | 2.3+755%1.0% | — | — | — | 0.3+0.4%0.2% | 0.5+0.9%0.5% | — | — | 0.3—0.2% | 0.5—0.4% | |
| Total liabilities | 220—95.6% | 220+14.1%95.6% | 157−2.3%75.8% | 146−11.0%64.1% | 189+45.1%76.8% | 192+104%109% | 160+144%81.6% | 164+112%125% | 130+83.2%128% | 94—74.5% | 66—62.2% | 77—62.6% | 71—47.5% | |
| Retained earnings | −1,311—−571% | −1,311—−571% | −1,236—−599% | −1,202—−527% | −1,165—−473% | −1,132—−640% | −1,034—−527% | −1,008—−765% | −956—−941% | −891—−705% | −867—−820% | −859—−695% | −825—−551% | |
| Shareholders' equity | 10—4.4% | 10—4.4% | 50+38.6%24.2% | 82—35.9% | 57—23.2% | −16−240%−8.8% | 36+91.3%18.4% | −32−229%−24.6% | −29−150%−28.5% | 11—8.8% | 19—17.8% | 25—20.3% | 57—38.3% | |
| Total liabilities and equity | 230—100% | 230+29.8%100% | 207+5.2%100% | 228+73.0%100% | 246+143%100% | 177+39.9%100% | 196+85.6%100% | 132+6.6%100% | 102−32.2%100% | 126—100% | 106—100% | 124—100% | 150—100% | |
| Shares outstanding | 94—— | 94+41.5%— | 90+47.1%— | 88+70.6%— | 78+73.6%— | 67+65.8%— | 62+129%— | 51+103%— | 45+77.1%— | 40—— | 27—— | 25—— | 25—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 11+19.3%11.2% | 3.7+70.4%15.5% | 3.4+0.5%8.6% | 2.0+14.4%11.0% | 2.0*+0.3%11.5% | 2.2+12.6%19.4% | 3.4+79.2%160% | 1.8+20.6%— | 2.0*+26.3%— | 1.9*—— | 1.9*—19.1% | 1.5—— | 1.6*—— | |
| Cash from operating activities | −160—−159% | −34*—−140% | −44*—−110% | −52—−279% | −30*—−171% | −36*—−322% | −33*—−1528% | −39—— | −25*—— | −24*—— | −28*—−276% | −28—— | −30*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—— | 0*—— | −0.0*—−0.1% | −0.0—— | — | |
| Intangible assets bought | — | — | — | — | −1.3*—−7.7% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −8.6—−8.6% | −7.5*—−31.2% | 16*—40.5% | −16—−85.8% | −1.3*—−7.7% | — | — | — | 0*−100%— | 0*—— | 29*—290% | 31—— | 12*—— | |
| Debt repaid | — | — | — | — | — | 0*—0.0% | 0*—0.0% | −43—— | — | — | — | — | — | |
| Shares issued | — | — | — | — | 97*—553% | 0*—0.0% | 70*—3272% | 30—— | 0*—— | — | — | — | 0*—— | |
| Cash from financing activities | 203+22.9%203% | 78*+334%323% | −1.5*−102%−3.8% | 29−57.4%154% | 99*+13186%562% | 18*−66.6%159% | 79*—3716% | 67+7870%— | 0.7*—— | 54*—— | −0.4*—−4.0% | 0.8—— | −0.4*—— | |
| Change in cash | 35+43.1%35.0% | 36*—152% | −29*−162%−72.9% | −39−237%−211% | 67*—384% | −27*−189%−237% | 47*+4493%2188% | 29+717%— | −24*—— | 30*—— | 1.0*—10.2% | 3.5—— | −18*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Verastem, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product revenue, net(total)$31 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Verastem, Inc. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Verastem, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Verastem, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dan Paterson | $2.3 M | $3.8 M | $958 K | $160 |
| 2024Dan Paterson | $2.5 M | $2.4 M | $741 K | $107 |
| 2023Dan Paterson | $3.6 M | $3.2 M | $623 K | $169 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Verastem, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 3 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officersResults announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share saleResults announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 14, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2020 | $100 M | Private placement after listing | $50 to $250 million | 21 | equity | SEC |
| Feb 2014 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Jul 2012 | $2 M | No. 3 | $2 to $10 million | 1 | equity | SEC |
| Nov 2011 | $20 M | No. 2 | $10 to $50 million | 36 | equity | SEC |
| Jul 2011 | $32 M | No. 1 | $10 to $50 million | 23 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Verastem, Inc.#
3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $165 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Assoc. Dir. Drug Substance Development & Manufacturing, CMCIndustrial Production Managers | 1 | $190 K |
| Senior Manager, Pharmacovigilance Operations SpecialistMedical Scientists, Except Epidemiologists | 1 | $156 K |
| Senior Manager, Statistical ProgrammingComputer Programmers | 1 | $165 K |
Where: Frisco, TX 1 · Canton, MI 1 · Shoreview, MN 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 3 | 3 | $165 K | 3 |
| FY2024 | 1 | 1 | $155 K | 1 |
| FY2023 | 1 | 1 | $134 K | 1 |
| FY2022 | 2 | 2 | $159 K | 2 |
| FY2021 | 1 | 1 | $145 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Verastem Inc.
FDA drug approvals: Verastem, Inc.#
1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2025.
| Approved | Drug | Kind |
|---|---|---|
| 2025-05-08 | Avmapki Fakzynja Co-Pack (Copackaged)new moleculeAvutometinib Potassium, Defactinib Hydrochloride · NDA219616 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (VERASTEM INC), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | 31 | · | · | · | · | · | · | · | · | · | · | 31 |
| 2019 | · | · | · | · | · | · | · | · | · | 40 | · | · | 40 |
| 2015 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 31 people | Restructuring planSEC 8-K | “Item 2.05 Costs Associated with Exit or Disposal Activities On February 27, 2020, the Company committed to an operational plan to reduce overall operating expenses, including the e…” | Filing | |
| 40 people | Restructuring planSEC 8-K | “Item 2.05 Costs Associated with Exit or Disposal Activities On October 28, 2019, the Company committed to an operational plan to reduce overall operating expenses, including the el…” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Verastem, Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of Verastem, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $373,496 in 2 trades. Awards, option exercises and shares withheld for tax are not counted.
- Results announced on 14 October 2026automatic update · Oct 14, 2026
Verastem, Inc. announced results on 14 October 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $24 million (up 114% from a year earlier) and a net loss of $75 million.
- Mutual funds: 110 funds hold $85 millionautomatic update · Jul 31, 2026
110 mutual funds in 1 country hold shares of Verastem, Inc. worth $85 million, about 15.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 85 funds added shares and 20 sold; on balance they bought $29 million. Share splits are not counted as trading.
How Verastem, Inc. compares in Biotechnology
- Market cap$1.1 B · higher than 69% of 726
- Revenue$31 M · higher than 54% of 647
- Net margin-677.7% · higher than 6% of 408
- Revenue growth209.1% · higher than 90% of 438
- Price / sales35.3× · lower than 22% of 339
- Price / book19.1× · lower than 8% of 534
- FCF yield-9.6% · higher than 58% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Verastem, Inc.🇺🇸 | $1.1 B | — | -677.7% | +209.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 19, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Verastem, Inc.? Verify and update this profile — free
Show Verastem, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.